Jonathan Beaudoin1, Jackie Szymonifka2, Zachary Lavender3, Roderick C Deaño4, Qing Zhou5, James L Januzzi6, Jagmeet P Singh6, Quynh A Truong2,7. 1. Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval, Québec City, QC, Canada. 2. Department of Biostatistics, New York University, New York, NY, USA. 3. Division of Medicine, Hartford Hospital, Hartford, CT, USA. 4. Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 5. Cardiac MR PET CT Program, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 6. Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 7. Division of Cardiology, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, NY, USA.
Abstract
BACKGROUND: Pulmonary hypertension (PH) is an adverse prognostic marker in patients undergoing cardiac resynchronization therapy (CRT). We sought to determine the relation of biomarkers of fibrosis [soluble ST2 (sST2), galectin-3], wall stretch [amino terminal pro-brain natriuretic peptide (NT-proBNP)], and necrosis [high-sensitivity troponin-I (hsTnI)] to PH severity in CRT patients. METHODS: Biomarkers and right ventricular systolic pressure (RVSP) were measured at CRT implant and 6-month later (n=111). PH was categorized into 3 groups based on RVSP: no (<35 mmHg), mild-moderate (35-60 mmHg), and severe (>60 mmHg). Patients were categorized as progressors (worsened PH), persistent PH (no change) and regressors (improved PH). Endpoints were 6-month CRT response and 2-year major adverse cardiac event (MACE). RESULTS: RVSP was associated with CRT nonresponse (P=0.02) and MACE (P=0.03). Severe PH patients had 5-fold increase risk for CRT nonresponse (OR 5.0, P=0.04) and MACE (HR 5.7, P=0.04) over non-PH patients. Progressors and persistent PH patients had >2-fold odds for CRT non-response (OR 2.8, P=0.45) and >11-fold increase in MACE compared to no PH patients or regressors (HR 11.6, P=0.02). Only NT-proBNP and sST2 were discernable between PH groups, with graded increase based on PH severity (both P≤0.02), and lower values in regressors versus non-regressors (both P≤0.01). Levels of sST2 decreased at 6 months in regressors (15 ng/mL, P=0.03) and increased slightly (3-8 ng/mL) in non-regressors, without difference for NT-proBNP (P=0.08). CONCLUSIONS: sST2 levels are related with PH severity in CRT patients. Serial sST2 changes after CRT implant suggests potential role to monitor PH after CRT. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: Pulmonary hypertension (PH) is an adverse prognostic marker in patients undergoing cardiac resynchronization therapy (CRT). We sought to determine the relation of biomarkers of fibrosis [soluble ST2 (sST2), galectin-3], wall stretch [amino terminal pro-brain natriuretic peptide (NT-proBNP)], and necrosis [high-sensitivity troponin-I (hsTnI)] to PH severity in CRT patients. METHODS: Biomarkers and right ventricular systolic pressure (RVSP) were measured at CRT implant and 6-month later (n=111). PH was categorized into 3 groups based on RVSP: no (<35 mmHg), mild-moderate (35-60 mmHg), and severe (>60 mmHg). Patients were categorized as progressors (worsened PH), persistent PH (no change) and regressors (improved PH). Endpoints were 6-month CRT response and 2-year major adverse cardiac event (MACE). RESULTS: RVSP was associated with CRT nonresponse (P=0.02) and MACE (P=0.03). Severe PH patients had 5-fold increase risk for CRT nonresponse (OR 5.0, P=0.04) and MACE (HR 5.7, P=0.04) over non-PH patients. Progressors and persistent PH patients had >2-fold odds for CRT non-response (OR 2.8, P=0.45) and >11-fold increase in MACE compared to no PH patients or regressors (HR 11.6, P=0.02). Only NT-proBNP and sST2 were discernable between PH groups, with graded increase based on PH severity (both P≤0.02), and lower values in regressors versus non-regressors (both P≤0.01). Levels of sST2 decreased at 6 months in regressors (15 ng/mL, P=0.03) and increased slightly (3-8 ng/mL) in non-regressors, without difference for NT-proBNP (P=0.08). CONCLUSIONS: sST2 levels are related with PH severity in CRT patients. Serial sST2 changes after CRT implant suggests potential role to monitor PH after CRT. 2019 Journal of Thoracic Disease. All rights reserved.
Authors: Anthony S L Tang; George A Wells; Mario Talajic; Malcolm O Arnold; Robert Sheldon; Stuart Connolly; Stefan H Hohnloser; Graham Nichol; David H Birnie; John L Sapp; Raymond Yee; Jeffrey S Healey; Jean L Rouleau Journal: N Engl J Med Date: 2010-11-14 Impact factor: 91.245
Authors: Gabe B Bleeker; Martin J Schalij; Petros Nihoyannopoulos; Paul Steendijk; Sander G Molhoek; Lieselot van Erven; Marianne Bootsma; Eduard R Holman; Ernst E van der Wall; Jeroen J Bax Journal: J Am Coll Cardiol Date: 2005-12-20 Impact factor: 24.094
Authors: Ravi V Shah; Annabel A Chen-Tournoux; Michael H Picard; Roland R J van Kimmenade; James L Januzzi Journal: Circ Heart Fail Date: 2009-05-14 Impact factor: 8.790
Authors: Neal A Chatterjee; Gaurav A Upadhyay; Gaurav Singal; Kimberly A Parks; G William Dec; Jagmeet P Singh; Gregory D Lewis Journal: JACC Heart Fail Date: 2014-04-30 Impact factor: 12.035
Authors: William A Zoghbi; David Adams; Robert O Bonow; Maurice Enriquez-Sarano; Elyse Foster; Paul A Grayburn; Rebecca T Hahn; Yuchi Han; Judy Hung; Roberto M Lang; Stephen H Little; Dipan J Shah; Stanton Shernan; Paaladinesh Thavendiranathan; James D Thomas; Neil J Weissman Journal: J Am Soc Echocardiogr Date: 2017-03-14 Impact factor: 5.251
Authors: Alberto Aimo; Giuseppe Vergaro; Andrea Ripoli; Antoni Bayes-Genis; Domingo A Pascual Figal; Rudolf A de Boer; Johan Lassus; Alexandre Mebazaa; Etienne Gayat; Tobias Breidthardt; Zaid Sabti; Christian Mueller; Hans-Peter Brunner-La Rocca; W H Wilson Tang; Justin L Grodin; Yuhui Zhang; Paulo Bettencourt; Alan S Maisel; Claudio Passino; James L Januzzi; Michele Emdin Journal: JACC Heart Fail Date: 2017-02-08 Impact factor: 12.035
Authors: Hicham Skali; Robert Gerwien; Timothy E Meyer; James V Snider; Scott D Solomon; Craig M Stolen Journal: J Cardiovasc Transl Res Date: 2016-10-31 Impact factor: 4.132
Authors: Alexander Goehler; Pamela M McMahon; Heidi S Lumish; Carol C Wu; Vidit Munshi; Michael Gilmore; Jonathan H Chung; Brian B Ghoshhajra; Daniel Mark; Quynh A Truong; G Scott Gazelle; Udo Hoffmann Journal: Circulation Date: 2014-07-11 Impact factor: 29.690